List view / Grid view
9 December 2014 | By Ergomed plc
Ergomed plc has announced that Aeterna Zentaris has signed an exclusive licence and technology transfer agreement with Sinopharm A-Think for the Chinese, Hong Kong and Macau markets for zoptarelin doxorubicin which is in Phase 3 development for treating endometrial cancer...
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
9 December 2014 | By Boehringer Ingelheim
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate)...
9 December 2014 | By Novo Nordisk
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment...
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
9 December 2014 | By GSK
GSK presented data at the British Thoracic Society meeting from a systematic analysis of 25 randomised control studies (RCTs), including a meta-analysis of three key efficacy outcomes, which explored the potential impact of the particle size of different ICS-containing asthma medicines, including Seretide/Advair (salmeterol/fluticasone proprionate) on patient outcomes...
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
8 December 2014 | By Novartis
Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy...
8 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from a cohort of patients in its ongoing Phase 1b trial (CheckMate -039) which evaluated PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), in patients with relapsed or refractory hematological malignancies (n=23)...
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
8 December 2014 | By Astellas
Astellas Pharma Europe Ltd. announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for enzalutamide (trade name XTANDI™)...
CAMO Software announced the launch of Service Pack 2014 for their all-in-one Multivariate Data Analysis (MVA) and Design of Experiments (DoE) software, The Unscrambler® X...
5 December 2014 | By Pierre Fabre
This award is recognition of both Pierre Fabre's expertise in dermatology, one of its development priorities, and of its ability to form public-private partnerships, such as that established with the University of Bordeaux...
5 December 2014 | By Abbott
Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition...
